Karyopharm Therapeutics Inc
NASDAQ:KPTI

Watchlist Manager
Karyopharm Therapeutics Inc Logo
Karyopharm Therapeutics Inc
NASDAQ:KPTI
Watchlist
Price: 6.31 USD -5.26% Market Closed
Market Cap: 107.6m USD

Wall Street
Price Targets

KPTI Price Targets Summary
Karyopharm Therapeutics Inc

Wall Street analysts forecast KPTI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KPTI is 14.89 USD with a low forecast of 6.06 USD and a high forecast of 22.05 USD.

Lowest
Price Target
6.06 USD
4% Downside
Average
Price Target
14.89 USD
136% Upside
Highest
Price Target
22.05 USD
249% Upside
Karyopharm Therapeutics Inc Competitors:
Price Targets
2162
KeyMed Biosciences Inc
40% Upside
VCYT
Veracyte Inc
20% Upside
600201
Jinyu Bio-Technology Co Ltd
25% Downside
688520
Sinocelltech Group Ltd
19% Upside
TLX
Telix Pharmaceuticals Ltd
128% Upside
BVXP
Bioventix PLC
121% Upside
4593
Healios KK
115% Upside
PRAX
Praxis Precision Medicines Inc
49% Upside

Revenue
Forecast

Revenue Estimate
Karyopharm Therapeutics Inc

For the last 12 years the compound annual growth rate for Karyopharm Therapeutics Inc's revenue is 58%. The projected CAGR for the next 4 years is 27%.

58%
Past Growth
27%
Estimated Growth
Estimates Accuracy
0%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Karyopharm Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
Karyopharm Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-79%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is KPTI's stock price target?
Price Target
14.89 USD

According to Wall Street analysts, the average 1-year price target for KPTI is 14.89 USD with a low forecast of 6.06 USD and a high forecast of 22.05 USD.

What is Karyopharm Therapeutics Inc's Revenue forecast?
Projected CAGR
27%

For the last 12 years the compound annual growth rate for Karyopharm Therapeutics Inc's revenue is 58%. The projected CAGR for the next 4 years is 27%.

Back to Top